NCT06248359 Association Between Postoperative Administration of L-Arginine and CSA-AKI
| NCT ID | NCT06248359 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Acute Kidney Injury |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,000 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,000 participants in total. It began in 2023-12-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the association between the the early administration of L-Arginine after CPB-assisted cardiac surgery and the incidence of CS-AKI in adult patients. To test if it can reduce the incidence of post-operative AKI.
Eligibility Criteria
Inclusion Criteria: * adult patients (over 18 years) * underwent CPB assisted cardiac surgery * admitted to ICU Exclusion Criteria: * congenital heart disease * underwent deep hypothermic circulatory arrest (DHCA) * with glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²
Contact & Investigator
Chong Lei
PRINCIPAL INVESTIGATOR
Xijing Hospital
Frequently Asked Questions
Who can join the NCT06248359 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06248359 currently recruiting?
Yes, NCT06248359 is actively recruiting participants. Contact the research team at zhengziyu@126.com for enrollment information.
Where is the NCT06248359 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06248359 clinical trial?
NCT06248359 is sponsored by Xijing Hospital. The principal investigator is Chong Lei at Xijing Hospital. The trial plans to enroll 7,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.